Laboratory testing for secondary osteoporosis evaluation

Clinical Biochemistry

Volumn 45, Issue 12, 2012, Pages 894-900

  Adler, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biliary cirrhosis; Celiac disease; Chronic Obstructive Pulmonary Disease; Glucocorticoids; Hyperparathyroidism; Hypogonadism; Inflammatory bowel disease; Osteoporosis; Rheumatoid arthritis

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; C REACTIVE PROTEIN; CALCIDIOL 1 MONOOXYGENASE; CALCIUM; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; LEVOTHYROXINE; LUTEINIZING HORMONE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PROLACTIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; THYROTROPIN;

ALCOHOL ABUSE; BARIATRIC SURGERY; BILIARY CIRRHOSIS; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CELIAC DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; CUSHING DISEASE; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FRACTURE; GLOMERULUS FILTRATION RATE; HEMOCHROMATOSIS; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; LACTATION; MASTOCYTOSIS; MULTIPLE MYELOMA; OSTEOPOROSIS; PANCREAS EXOCRINE INSUFFICIENCY; PARATHYROID DISEASE; PHYSICAL EXAMINATION; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; WALKING DIFFICULTY;

ALCOHOLISM; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; DIAGNOSIS, DIFFERENTIAL; ENDOCRINE SYSTEM DISEASES; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HEMOCHROMATOSIS; HUMANS; MASTOCYTOSIS; MULTIPLE MYELOMA; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84863865326     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.024     Document Type: Review

References (61)

1. Riggs B.L., Melton L.J. Involutional osteoporosis. N Engl J Med 1986, 314:1676-1686.
2. Adler R.A. Osteoporosis in men. Osteoporosis - pathophysiology and clinical management 2010, 545-557. Humana Press, New York. 2nd Edition. R.A. Adler (Ed.).
3. Cohen A., Dempster D.W., Recker R.R., Stein E.M., Lappe J.M., Zhou H., et al. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2011, 96:3095-3105.
4. Rosen C.J., Kurland E.S., Vereault D., Adler R.A., Rackoff P.J., Craig W.Y., et al. An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998, 83:2286-2290.
5. Levis S., Gomez A., Jimenez C., Veras L., Ma F., Lai S., et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab 2005, 90:1557-1562.
6. Binkley N., Novotny R., Krueger D., Kawahara T., Daida Y.G., Lensmeyer G., et al. Low vitamin D status despite adequate sun exposure. J Clin Endocrinol Metab 2007, 92:2130-2135.
7. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The 2011 dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
8. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Murad M.H., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
9. Jackson R.D., Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Curr Osteoporos Rep 2007, 5:153-159.
10. Binkley N., Krueger D.C., Morgan S., Wiebe D. Current status of clinical 25-hydroxyvitamin D measurement: an assessment of between-laboratory agreement. Clin Chim Acta 2010, 411:1976-1982.
11. Brock K., Huang W.Y., Fraser D.R., Ke L., Tseng M., Stolzenberg-Solomon R., et al. Low vitamin D status is associated with physical inactivity, obesity, and low vitamin D intake in a large US sample of healthy middle-aged men and women. J Steroid Biochem Mol Biol 2010, 121:462-466.
12. Priemel M., von Domarus C., Klatte T.O., Kessler S., Schile J., Meier S., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010, 25:305-312.
13. Jamal S.A., West S.L., Miller P.D. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2011, published on line 8 September.
14. Zerwekh J.E., Sakhaee K., Breslau N.A., Gottschalk F., Pak C.Y. Impaired bone formation in male idiopathic osteoporosis: further reduction in the presence of concomitant hypercalciuria. Osteoporos Int 1992, 2:128-134.
15. Asplin J.R., Bauer K.A., Kinder J., Muller G., Cox B.J., Parks J.H., et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003, 63:662-669.
16. Kurland E.S., Rosen C.J., Cosman F., McMahon D., Chan F., Shane E., et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997, 82:2799-2805.
17. Van Pottelbergh I., Goemaere S., Zmierczak H., Kaufman J.M. Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab 2004, 89:4949-4953.
18. Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.T., Hodgson S.F., et al. AACE Osteoporosis Task Force, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010, 16(Suppl 3):1-37.
19. U.S.Preventive Services Task Force Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011, 154:356-364.
20. Lim L.S., Hoeksema L.J., Sherin K. ACPM Prevention Practice Committee, screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009, 36:366-375.
21. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2008, National Osteoporosis Foundation, Washington DC.
22. Biver E., Chopin F., Coiffier G., Brentano T.F., Bouvard B., Garnero P., et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine 2012, 79:20-25.
23. Dreyer P., Vieira J.G.H. Bone turnover assessment: a good surrogate marker?. Arq Bras Endocrinol Metabol 2010, 54:99-105.
24. Civitelli R., Armamento-Villareal R., Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009, 20:843-851.
25. Vasikaran S., Cooper C., Eastell R., Griesmacher A., Morris H.A., Trenti T., et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011, 49:1271-1274.
26. Hoppe E., Bouvard B., Royer M., Audran M., Legrand E. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine 2010, 77:306-312.
27. Iranmanesh A., Lawson D., Veldhuis J.D. Glucose ingestion acutely lowers pulsatile LH and basal testosterone secretion in men. Am J Physiol Metab 2012, published on line Jan 17.
28. Rosner W., Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 2010, 95:4542-4548.
29. Bhasin S., Pencina M., Jasuja G.K., Travison T.G., Coviello A., Orwoll E., et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrophotometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011, 96:2430-2439.
30. Mazer N.A. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone, and cortisol: with illustrative examples from male and female populations. Steroids 2009, 74:512-519.
31. Vestergaard P., Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 2003, 13:585-593.
32. K. Burman, Thyroid disease and osteoporosis, Hosp Practice (Minneap) 32 (1997) 71-73, 78-85, 85-86.
33. Weinstein R.S. Clinical practice, glucocorticoid-induced bone disease. N Engl J Med 2011, 365:62-70.
34. Adler R.A., Hochberg M.C., Adler R.A. Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest 2011, 34:481-484.
35. Bilezikian J.P., Khan A.A., Potts J.T. Third International Workshop of the Management of Asymptomatic Primary Hyperparathyroidism, guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339.
36. Sturgeon C.M., Sprague S.M., Metcalfe W. Variation in parathyroid hormone immunoassay results - a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011, 26:3440-3445.
37. Kurra S., Siris E. Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures. Diabetes Metab Res Rev 2011, 27:430-435.
38. Tignor A.S., Wu B.U., Whitlock T.L., Lopez R., Repas K., Banks P.A., et al. High prevalence of low-trauma fracture in chronic pancreatitis. Am J Gastroenterol 2010, 105:2680-2686.
39. Fournier M.R., Targownik L.E., Leslie W.D. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas 2009, 64:9-13.
40. Furlanetto T.W., Faulhaber G.A. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011, 171:1391-1392.
41. Viegas M., Vasconcelos R.S., Neves A.P., Diniz E.T., Bandeira F. Bariatric surgery and bone metabolism: a systematic review. Arq Bras Endocrinol Metabol 2010, 54:158-163.
42. Su C.W., Chan C.C., Hung H.H., Huo T.I., Huang Y.H., Li C.P., et al. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol 2009, 43:876-883.
43. Bianchi M.L., Bardella M.T. Bone in celiac disease. Osteoporos Int 2008, 19:1705-1716.
44. Evans K.E., Sanders D.S. What is the use of biopsy and antibodies in celiac disease diagnosis?. J Intern Med 2011, 269:572-581.
45. Rozenberg O., Lerner A., Pacht A., Grinberg M., Reginashvili D., Henig C., et al. A new algorithm for the diagnosis of celiac disease. Cell Mol Immunol 2011, 8:146-149.
46. Moyer T.P., Highsmith W.E., Smyrk T.C., Gross J.B. Hereditary hemochromatosis: laboratory evaluation. Clin Chim Acta 2011, 412:1485-1492.
47. Carmona L., Cross M., Williams B., Lassere M., March L. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010, 24:733-745.
48. Biskobing D.M. COPD and osteoporosis. Chest 2002, 121:609-620.
49. Adler R.A., Funkhouser H.L., Petkov V.I., Berger M.M. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003, 325:1-6.
50. Morse L.R., Battaglino R.A., Stolzmann K.L., Hallett L.D., Waddimba A., Gagnon D., et al. Osteoporotic fractures and hospitalization risk in chronic spinal cord injury. Osteoporos Int 2009, 20:385-392.
51. Fink H.A., Kuskowski M.A., Taylor B.C., Schouboe J.T., Orwoll E.S., Ensrud K.E. Osteoporotic Fractures in Men (MrOS) Study Group, association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 2008, 19:1277-1282.
52. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispensieri A., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
53. Kang S.Y., Suh J.T., Lee H.J., Yoon H.J., Lee W.I. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005, 84:588-593.
54. Schwartz L.B., Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:641-657.
55. Kovacs C.S. Calcium and bone metabolism during pregnancy and lactation. Endocrinol Metab Clin North Am 2011, 40:795-826.
56. Segal E., Hochberg I., Weisman Y., Ish-Shalom S. Severe postpartum osteoporosis with increased PTHrP during lactation in a patient after total thyroidectomy and parathyroidectomy. Osteoporos Int 2011, 22:2907-2911.
57. Lee R.H., Lyles K.W., Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010, 8:34-46.
58. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004, 184:503-508.
59. Smith M.R. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007, 13:241-245.
60. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002, 87:4431-4437.
61. Ryan C.S., Petkov V.I., Adler R.A. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011, 22:1845-1853.